Opinion
Video
Efficacy and Durability: New Therapies vs Aflibercept 2mg
Author(s):
Experts reflect on the current information available on the safety and durability of second-generation agents aflibercept 8 mg and faricimab.
Summary
In this segment, the discussion centers on the efficacy and durability of different anti-VEGF agents, specifically aflibercept 2 mg, 8 mg, and faricimab. Diana Do, MD emphasizes the challenges in making direct head-to-head comparisons between these agents, as they were not tested against each other in clinical trials with the same design. The focus shifts particularly to durability gains between therapies, highlighting the need for new clinical trials designed for such comparisons. Experts agree that increased durability while maintaining vision anatomy and perception is the gold standard of care for retinal disease therapies.
David Eichenbaum, MD raises a question about the drying efficacy of aflibercept 8 milligrams compared to aflibercept 2 mg in wet AMD. Seenu Hariprasad, MD responds, stating that there is good level-one evidence demonstrating that the second-generation agents, including aflibercept 8 mg, exhibit superior drying effects compared to the older generation agents like aflibercept 2 mg. He notes an increase in drying effect with the new generation agents and emphasizes the importance of drying in controlling vision outcomes.
This summary was AI-generated and edited for clarity.
